Medtronic Plc's MDT Q2 FY22 sales of $7.85 billion increased 3% Y/Y as reported and 2% on an organic basis, missing the consensus of $7.96 billion. Q2 adjusted EPS of $1.32 increased 30% from $1.02 a year ago, surpassing the analyst consensus of $1.29.
- The company says that the Q2 results reflect the unfavorable market impact of COVID-19 and health system labor shortages on medical device procedure volumes, primarily in the U.S.
- Sales at Medtronic's heart devices unit jumped 3.7% Y/Y (3.3% on constant currency) to $2.83 billion.
- Spine & neurosurgery product segment sales increased 3.5% (3.1% constant currency) to $2.14 billion.
- Diabetes revenue of $585 million increased 2% as reported and 1% organic.
- Guidance: Medtronic expects the market impact of the pandemic and healthcare system staffing challenges to continue into the H2 of FY22.
- It now forecasts FY22 revenue growth of 7-8% on an organic basis versus the prior expectation of approximately 9%
- Medtronic reiterated its adjusted EPS guidance of $5.65 - $5.75 (consensus of $5.71).
- Price Action: MDT shares are down 0.50% at $116.3 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in